Chromo. with all due respect to your biotech / science background ....do U understand the business risks here ?
This is going to be a half glass full post ...not intended as FUD altho some here will definitely read it that way .
We have had a fantastic run up recently due to better then expected cash on hand numbers and Dr Denners aggressive moves .
Your average costs as per your previous posts is $5.24 .
Any thought of selling some here to reduce your exposure ?
So the risks going forward that no one wants to discuss .
1) IF AMRN / Kaiser have stopped dispensing Vascepa in the MITIGATE trial , theres no 2 yr CV data to compare / support the R-IT numbers in the US population .
Therefore theres no additional clinical trial data to persuade Germany to lift its evidence of benefit rating from 11b ( 2b )
2) Without the additional clinical data France , Italy and Spain may follow Germany and decide for now not to provide reimbursement ...or if they do ...only for the very high risk , secondary prevention R-IT profile patients . So minimal sales
3) Sales in the UK are likely to be minimal
4) Script numbers start declining again in the US as more formularies drop coverage ...or simply raise the tier rating forcing higher copays for Brand Vascepa .
5) When U are running a business you can only cut / down size so much . AMRN may have done as much as they can in this area in the US ..or be close to it.
6) As poster oneragman mentioned ...risk of dilution . Reduced sales in the US , less room for cost cutting , minimal sales in the UK..... spells eventual dilution
7). Theres a real chance IMHO that no BP is interested in this Co .
Oh by the way ....For those who think China is going to bail U out ....chk out their negotiations for Paxlovid .
Chromo ...appreciate your posts .
Good luck with whatever U decide to do
Kiwi
AI
Market Data 
Markets 
